Telecommunications company T-Mobile, US Inc. (NYSE:TMUS) reports a Q4 2013 loss of $19 million, or $0.03 per diluted share, which would have been better than the Thomson Reuters consensus of $(0.13). In the same period last year, the company had a profit of $42 million, or $(0.01) per diluted share. Revenues totaled $6.9 billion versus $4.9 billion in the prior-year period. T-Mobile ended the fourth quarter of 2013 with approximately 46.7 million customers, an increase of 1.645 million total customers from the end of the third quarter of 2013. T-Mobile significantly grew its total branded customer base, with 981,000 net customer additions during the quarter.

Branded postpaid net customer additions of 869,000, including 800,000 phone net additions, continued the momentum seen in the second and third quarters, reflecting continued low branded postpaid churn and significantly higher gross additions. For full-year 2014, the company expects Adjusted EBITDA to be in the range of $5.7 to $6.0 billion. Cash capital expenditures are expected to be in the range of $4.3 to $4.6 billion. TMUS was trading at $32.31 after hours.

Tesla (NASDAQ:TSLA) continues to see strong upside momentum take it to fresh record highs, recently touching a pre-market top of $230.79 and putting it on track to outpace the high of $218.36 established in Monday’s regular session.

ImmunoCellular Therapeutics (NYSEMKT:IMUC) is vaulting higher this morning after it announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.